This invention relates generally to treatment of solid cancers. More particularly, the invention relates to nozzle inserts, of a charged particle cancer therapy system, for controlling charged particle density, energy, distribution, and/or shape.
Cancer Treatment
Proton therapy works by aiming energetic ionizing particles, such as protons accelerated with a particle accelerator, into a target tumor. These particles damage the DNA of cells, ultimately causing their death. Cancerous cells, because of their high rate of division and their reduced ability to repair damaged DNA, are particularly vulnerable to attack on their DNA.
Patents related to the current invention are summarized here.
Proton Beam Therapy System
F. Cole, et. al. of Loma Linda University Medical Center “Multi-Station Proton Beam Therapy System”, U.S. Pat. No. 4,870,287 (Sep. 26, 1989) describe a proton beam therapy system for selectively generating and transporting proton beams from a single proton source and accelerator to a selected treatment room of a plurality of patient treatment rooms.
Imaging
P. Adamee, et. al. “Charged Particle Beam Apparatus and Method for Operating the Same”, U.S. Pat. No. 7,274,018 (Sep. 25, 2007) and P. Adamee, et. al. “Charged Particle Beam Apparatus and Method for Operating the Same”, U.S. Pat. No. 7,045,781 (May 16, 2006) describe a charged particle beam apparatus configured for serial and/or parallel imaging of an object.
K. Hiramoto, et. al. “Ion Beam Therapy System and its Couch Positioning System”, U.S. Pat. No. 7,193,227 (Mar. 20, 2007) describe an ion beam therapy system having an X-ray imaging system moving in conjunction with a rotating gantry.
C. Maurer, et. al. “Apparatus and Method for Registration of Images to Physical Space Using a Weighted Combination of Points and Surfaces”, U.S. Pat. No. 6,560,354 (May 6, 2003) described a process of X-ray computed tomography registered to physical measurements taken on the patient's body, where different body parts are given different weights. Weights are used in an iterative registration process to determine a rigid body transformation process, where the transformation function is used to assist surgical or stereotactic procedures.
M. Blair, et. al. “Proton Beam Digital Imaging System”, U.S. Pat. No. 5,825,845 (Oct. 20, 1998) describe a proton beam digital imaging system having an X-ray source that is movable into a treatment beam line that can produce an X-ray beam through a region of the body. By comparison of the relative positions of the center of the beam in the patient orientation image and the isocentre in the master prescription image with respect to selected monuments, the amount and direction of movement of the patient to make the best beam center correspond to the target isocentre is determined.
S. Nishihara, et. al. “Therapeutic Apparatus”, U.S. Pat. No. 5,039,867 (Aug. 13, 1991) describe a method and apparatus for positioning a therapeutic beam in which a first distance is determined on the basis of a first image, a second distance is determined on the basis of a second image, and the patient is moved to a therapy beam irradiation position on the basis of the first and second distances.
Problem
There exists in the art of charged particle irradiation therapy a need to control energy, cross-sectional beam shape, and/or focal point, of the charged particle beam, where the controls are individualized to individual patients and/or individual tumor shapes.
The invention comprises a charged particle beam control system.
A more complete understanding of the present invention is derived by referring to the detailed description and claims when considered in connection with the Figures, wherein like reference numbers refer to similar items throughout the Figures.
Elements and steps in the figures are illustrated for simplicity and clarity and have not necessarily been rendered according to any particular sequence. For example, steps that are performed concurrently or in different order are illustrated in the figures to help improve understanding of embodiments of the present invention.
The invention comprises a charged particle beam control tray in a nozzle of a charged particle cancer therapy apparatus and method of use thereof.
In one embodiment, one or more trays are inserted into the positively charged particle beam path, such as at an exit port of a gantry nozzle in close proximity to the patient. Each tray holds an insert, such as a patient specific insert for controlling the energy, focus depth, and/or shape of the charged particle beam. Examples of inserts include a range shifter, a compensator, an aperture, a ridge filter, and a blank. Optionally and preferably, each tray communicates a held and positioned insert to a main controller of the charged particle cancer therapy system.
In another embodiment, a treatment delivery control system (TDCS) or main controller is used to control multiple aspects of the cancer therapy system, including one or more of: an imaging system, such as a CT or PET; a positioner, such as a couch or patient interface module; an injector or injection system; a radio-frequency quadrupole system; a ring accelerator or synchrotron; an extraction system; an irradiation plan; and a display system. The TDCS is preferably a control system for automated cancer therapy once the patient is positioned. The TDCS integrates output of one or more of the below described cancer therapy system elements with inputs of one or more of the below described cancer therapy system elements. More generally, the TDCS controls or manages input and/or output of imaging, an irradiation plan, and charged particle delivery.
In another embodiment, the charged particle tomography apparatus is used in combination with a charged particle cancer therapy system. For example, tomographic imaging of a cancerous tumor is performed using charged particles generated with an injector, accelerator, and guided with a delivery system. The cancer therapy system uses the same injector, accelerator, and guided delivery system in delivering charged particles to the cancerous tumor. For example, the tomography apparatus and cancer therapy system use a common raster beam method and apparatus for treatment of solid cancers. More particularly, the invention comprises a multi-axis and/or multi-field raster beam charged particle accelerator used in tomography and cancer therapy. Optionally, the system independently controls patient translation position, patient rotation position, two-dimensional beam trajectory, delivered radiation beam energy, delivered radiation beam intensity, beam velocity, timing of charged particle delivery, and/or distribution of radiation striking healthy tissue. The system operates in conjunction with a negative ion beam source, synchrotron, patient positioning, imaging, and/or targeting method and apparatus to deliver an effective and uniform dose of radiation to a tumor while distributing radiation striking healthy tissue.
Charged Particle Beam Therapy
Throughout this document, a charged particle beam therapy system, such as a positively charged ion beam, a cation beam, a proton beam, hydrogen ion beam, a cation beam comprising atoms consisting of two to six protons per atom, or carbon ion beam, is described. Herein, the charged particle beam therapy system is described using a proton beam. However, the aspects taught and described in terms of a proton beam are not intended to be limiting to that of a proton beam and are illustrative of a charged particle beam system. Any of the techniques described herein are equally applicable to any charged particle beam system.
Referring now to
An exemplary method of use of the charged particle beam system 100 is provided. The main controller 110 controls one or more of the subsystems to accurately and precisely deliver protons to a tumor of a patient. For example, the main controller 110 obtains an image, such as a portion of a body and/or of a tumor, from the imaging system 170. The main controller 110 also obtains position and/or timing information from the patient interface module 150. The main controller 110 then optionally controls the injection system 120 to inject a proton into a synchrotron 130. The synchrotron typically contains at least an accelerator system 132 and an extraction system 134. The main controller 110 preferably controls the proton beam within the accelerator system, such as by controlling speed, trajectory, and timing of the proton beam. The main controller 110 then controls extraction of a proton beam from the accelerator through the extraction system 134. For example, the controller controls timing, energy, and/or intensity of the extracted beam. The controller 110 also preferably controls targeting of the proton beam through the scanning/targeting/delivery system 140 to the patient interface module 150. One or more components of the patient interface module 150, such as translational and rotational position of the patient, are preferably controlled by the main controller 110. Further, display elements of the display system 160 are preferably controlled via the main controller 110. Displays, such as display screens, are typically provided to one or more operators at one or more control stations, and/or to one or more patients. In one embodiment, the main controller 110 times the delivery of the proton beam from all systems, such that protons are delivered in an optimal therapeutic manner to the tumor of the patient.
Herein, the main controller 110 refers to a single system controlling the charged particle beam system 100, to a single controller controlling a plurality of subsystems controlling the charged particle beam system 100, or to a plurality of individual controllers controlling one or more sub-systems of the charged particle beam system 100.
Referring system now to
Proton Beam Extraction
Referring now to
In the proton extraction process, an RF voltage is applied across the first pair of blades, where the first blade 312 of the first pair of blades is on one side of the circulating proton beam path 264 and the second blade 314 of the first pair of blades is on an opposite side of the circulating proton beam path 264. The applied RF field applies energy to the circulating charged-particle beam. The applied RF field alters the orbiting or circulating beam path of the protons slightly from the original central beamline 264 to an altered circulating beam path 265. Upon a second pass of the protons through the RF cavity system, the RF field further moves the protons off of the original proton beamline 264. For example, if the original beamline is considered as a circular path, then the altered beamline is slightly elliptical. The applied RF field is timed to apply outward or inward movement to a given band of protons circulating in the synchrotron accelerator. Each orbit of the protons is slightly more off axis compared to the original circulating beam path 264. Successive passes of the protons through the RF cavity system are forced further and further from the original central beamline 264 by altering the direction and/or intensity of the RF field with each successive pass of the proton beam through the RF field.
The RF voltage is frequency modulated at a frequency about equal to the period of one proton cycling around the synchrotron for one revolution or at a frequency than is an integral multiplier of the period of one proton cycling about the synchrotron. The applied RF frequency modulated voltage induces a betatron oscillation. For example, the oscillation is a sine wave motion of the protons. The process of timing the RF field to a given proton beam within the RF cavity system is repeated thousands of times with each successive pass of the protons being moved approximately one micrometer further off of the original central beamline 264. For clarity, the approximately 1000 changing beam paths with each successive path of a given band of protons through the RF field are illustrated as the altered beam path 265.
With a sufficient sine wave betatron amplitude, the altered circulating beam path 265 touches and/or traverses a material 330, such as a foil or a sheet of foil. The foil is preferably a lightweight material, such as beryllium, a lithium hydride, a carbon sheet, or a material having low nuclear charge components. Herein, a material of low nuclear charge is a material composed of atoms consisting essentially of atoms having six or fewer protons. The foil is preferably about 10 to 150 microns thick, is more preferably about 30 to 100 microns thick, and is still more preferably about 40 to 60 microns thick. In one example, the foil is beryllium with a thickness of about 50 microns. When the protons traverse through the foil, energy of the protons is lost and the speed of the protons is reduced. Typically, a current is also generated, described infra. Protons moving at a slower speed travel in the synchrotron with a reduced radius of curvature 266 compared to either the original central beamline 264 or the altered circulating path 265. The reduced radius of curvature 266 path is also referred to herein as a path having a smaller diameter of trajectory or a path having protons with reduced energy. The reduced radius of curvature 266 is typically about two millimeters less than a radius of curvature of the last pass of the protons along the altered proton beam path 265.
The thickness of the material 330 is optionally adjusted to create a change in the radius of curvature, such as about ½, 1, 2, 3, or 4 mm less than the last pass of the protons 265 or original radius of curvature 264. Protons moving with the smaller radius of curvature travel between a second pair of blades. In one case, the second pair of blades is physically distinct and/or is separated from the first pair of blades. In a second case, one of the first pair of blades is also a member of the second pair of blades. For example, the second pair of blades is the second blade 314 and a third blade 316 in the RF cavity system 310. A high voltage DC signal, such as about 1 to 5 kV, is then applied across the second pair of blades, which directs the protons out of the synchrotron through an extraction magnet 292, such as a Lamberson extraction magnet, into a transport path 268.
Control of acceleration of the charged particle beam path in the synchrotron with the accelerator and/or applied fields of the turning magnets in combination with the above described extraction system allows for control of the intensity of the extracted proton beam, where intensity is a proton flux per unit time or the number of protons extracted as a function of time. For example, when a current is measured beyond a threshold, the RF field modulation in the RF cavity system is terminated or reinitiated to establish a subsequent cycle of proton beam extraction. This process is repeated to yield many cycles of proton beam extraction from the synchrotron accelerator. Intensity control of the charged particle beam is further described, infra.
In another embodiment, instead of moving the charged particles to the material 330, the material 330 is mechanically moved to the circulating charged particles. Particularly, the material 330 is mechanically or electromechanically translated into the path of the circulating charged particles to induce the extraction process, described supra.
In either case, because the extraction system does not depend on any change in magnetic field properties, it allows the synchrotron to continue to operate in acceleration or deceleration mode during the extraction process. Stated differently, the extraction process does not interfere with synchrotron acceleration. In stark contrast, traditional extraction systems introduce a new magnetic field, such as via a hexapole, during the extraction process. More particularly, traditional synchrotrons have a magnet, such as a hexapole magnet, that is off during an acceleration stage. During the extraction phase, the hexapole magnetic field is introduced to the circulating path of the synchrotron. The introduction of the magnetic field necessitates two distinct modes, an acceleration mode and an extraction mode, which are mutually exclusive in time. The herein described system allows for acceleration and/or deceleration of the proton during the extraction step without the use of a newly introduced magnetic field, such as by a hexapole magnet.
Charged Particle Beam Intensity Control
Control of applied field, such as a radio-frequency (RF) field, frequency and magnitude in the RF cavity system 310 allows for intensity control of the extracted proton beam, where intensity is extracted proton flux per unit time or the number of protons extracted as a function of time.
Still referring
The amplified signal or measured intensity signal resulting from the protons passing through the material 330 is optionally used in monitoring the intensity of the extracted protons and is preferably used in controlling the intensity of the extracted protons. For example, the measured intensity signal is compared to a goal signal, which is predetermined in an irradiation of the tumor plan. The difference between the measured intensity signal and the planned for goal signal is calculated. The difference is used as a control to the RF generator. Hence, the measured flow of current resulting from the protons passing through the material 330 is used as a control in the RF generator to increase or decrease the number of protons undergoing betatron oscillation and striking the material 330. Hence, the voltage determined off of the material 330 is used as a measure of the orbital path and is used as a feedback control to control the RF cavity system.
In one example, the intensity controller subsystem 340 preferably additionally receives input from: (1) a detector 350, which provides a reading of the actual intensity of the proton beam and (2) an irradiation plan 360. The irradiation plan provides the desired intensity of the proton beam for each x, y, energy, and/or rotational position of the patient/tumor as a function of time. Thus, the intensity controller 340 receives: (1) the desired intensity from the irradiation plan 350, (2) the actual intensity from the detector 350, and/or (3) a measure of intensity from the material 330 and adjusts the radio-frequency field in the RF cavity system 310 to yield an intensity of the proton beam that matches the desired intensity from the irradiation plan 360.
Charged Particle Beam Control
As described, supra, the photons striking the material 330 is a step in the extraction of the protons from the synchrotron 130. Hence, the measured intensity signal is used to change the number of protons per unit time being extracted, which is referred to as intensity of the proton beam. The intensity of the proton beam is thus under algorithm control. Further, the intensity of the proton beam is controlled separately from the velocity of the protons in the synchrotron 130. Hence, intensity of the protons extracted and the energy of the protons extracted are independently variable.
For example, protons initially move at an equilibrium trajectory in the synchrotron 130. An RF field is used to excite the protons into a betatron oscillation. In one case, the frequency of the protons orbit is about 10 MHz. In one example, in about one millisecond or after about 10,000 orbits, the first protons hit an outer edge of the target material 130. The specific frequency and corresponding energy of the charged particle beam is dependent upon the period of the orbit. Upon hitting the material 130, the protons push electrons through the foil to produce a current. The current is converted to voltage and amplified to yield a measured intensity signal. The measured intensity signal is used as a feedback input to control the applied RF magnitude, RF frequency, or RF field. Preferably, the measured intensity signal is compared to a target signal and a measure of the difference between the measured intensity signal and target signal is used to adjust the applied RF field in the RF cavity system 310 in the extraction system to control the intensity of the protons in the extraction step. Stated again, the signal resulting from the protons striking and/or passing through the material 130 is used as an input in RF field modulation. An increase in the magnitude of the RF modulation results in protons hitting the foil or material 130 sooner. By increasing the RF, more protons are pushed into the foil, which results in an increased intensity, or more protons per unit time, of protons extracted from the synchrotron 130. Notably, the intensity control process is independent of the magnetic fields used to control velocity of the charged particles in the circulating beam path 264. Thus, (1) energy, velocity of the extracted protons and (2) intensity, protons per unit time of the extracted protons are both independently variable and independently controllable.
In another example, a detector 350 external to the synchrotron 130 is used to determine the flux of protons extracted from the synchrotron and a signal from the external detector is used to alter the RF field or RF modulation in the RF cavity system 310. Here the external detector generates an external signal, which is used in a manner similar to the measured intensity signal, described in the preceding paragraphs. Preferably, an algorithm or irradiation plan 360 is used as an input to the intensity controller 340, which controls the RF field modulation by directing the RF signal in the betatron oscillation generation in the RF cavity system 310. The irradiation plan 360 preferably includes the desired intensity of the charged particle beam as a function of time, energy of the charged particle beam as a function of time, for each patient rotation position, and/or for each x-, y-position of the charged particle beam.
In yet another example, when a current from material 130 resulting from protons passing through or hitting material is measured beyond a threshold, the RF field modulation in the RF cavity system is terminated or reinitiated to establish a subsequent cycle of proton beam extraction. This process is repeated to yield many cycles of proton beam extraction from the synchrotron accelerator.
In still yet another embodiment, intensity modulation of the extracted proton beam is controlled by the main controller 110. The main controller 110 optionally and/or additionally controls timing of extraction of the charged particle beam and energy of the extracted proton beam. Optionally and preferably, the main controller 110 directly controls all subsystems of the charged particle cancer therapy system 100 and/or the subsystems thereof. Optionally and preferably, the subsystems of the charged particle cancer therapy systems communicate solely via the main controller 110.
The benefits of the system include a multi-dimensional scanning system. Particularly, the system allows independence in: (1) energy of the protons extracted and (2) intensity of the protons extracted. That is, energy of the protons extracted is controlled by an energy control system and an intensity control system controls the intensity of the extracted protons. The energy control system and intensity control system are optionally independently controlled. Preferably, the main controller 110 controls the energy control system and the main controller 110 simultaneously controls the intensity control system to yield an extracted proton beam with controlled energy and controlled intensity where the controlled energy and controlled intensity are independently variable. Thus the irradiation spot hitting the tumor is under independent control of:
In addition, the patient is optionally independently translated and/or rotated relative to a translational axis of the proton beam at the same time.
Charged Particle Control
Referring now to
Beam Control Tray
Referring now to
For clarity of presentation and without loss of generality, the means for holding the patient specific tray insert 510 in the tray frame 410 of the beam control tray assembly 400 is illustrated as a set of recessed set screws 415. However, the means for holding the patient specific tray insert 510 relative to the rest of the beam control tray assembly 400 is optionally any mechanical and/or electromechanical positioning element, such as a latch, clamp, fastener, clip, slide, strap, or the like. Generally, the means for holding the patient specific tray insert 510 in the beam control tray 400 fixes the tray insert and tray frame relative to one another even when rotated along and/or around multiple axes, such as when attached to a charged particle cancer therapy system 100 dynamic gantry nozzle 610 that moves in three-dimensional space relative to a given patient position. As illustrated in
Still referring to
Patient Specific Tray Insert
Referring again to
Still referring to
Slot Occupancy/Identification
Referring again to
In a first example, one or more of the patient specific tray inserts 510, such as the range shifter insert 511, the patient specific ridge filter insert 512, the aperture insert 513, the compensator insert 514, or the blank insert 515 include an identifier 520 and/or and a first electromechanical identifier plug 530. The identifier 520 is optionally a label, a radio-frequency identification tag, a barcode, a 2-dimensional bar-code, a matrix-code, or the like. The first electromechanical identifier plug 530 optionally includes memory programmed with the particular patient specific tray insert information and a connector used to communicate the information to the beam control tray assembly 400 and/or to the main controller 110. As illustrated in
In a second example, the beam control tray assembly 400 uses the second electromechanical identifier plug to send occupancy, position, and/or identification information related to the type or patient specific tray insert 510 associated with the beam control tray assembly to the main controller 110. For example, a first tray assembly is configured with a first tray insert and a second tray assembly is configured with a second tray insert. The first tray assembly sends information to the main controller 110 that the first tray assembly holds the first tray insert, such as a range shifter, and the second tray assembly sends information to the main controller 110 that the second tray assembly holds the second tray insert, such as an aperture. The second electromechanical identifier plug optionally contains programmable memory for the operator to input the specific tray insert type, a selection switch for the operator to select the tray insert type, and/or an electromechanical connection to the main controller. The second electromechanical identifier plug associated with the beam control tray assembly 400 is optionally used without use of the first electromechanical identifier plug 530 associated with the tray insert 510.
In a third example, one type of tray connector/communicator 430 is used for each type of patient specific tray insert 510. For example, a first connector/communicator type is used for holding a range shifter insert 511, while a second, third, fourth, and fifth connector/communicator type is used for trays respectively holding a patient specific ridge filter insert 512, an aperture insert 513, a compensator insert 514, or a blank insert 515. In one case, the tray communicates tray type with the main controller. In a second case, the tray communicates patient specific tray insert information with the main controller, such as an aperture identifier custom built for the individual patient being treated.
Tray Insertion/Coupling
Referring now to
Referring now to
Still referring to
Tray Receiver Assembly Retraction
Referring again to
For clarity of presentation and without loss of generality, several examples of loading patient specific tray inserts into tray assemblies with subsequent insertion into an positively charged particle beam path proximate a gantry nozzle are provided.
In a first example, a single beam control tray assembly 400 is used to control the charged particle beam 268 in the charged particle cancer therapy system 100. In this example, a patient specific range shifter insert 511, which is custom fabricated from a patient, is loaded into a patient specific tray insert 510 to form a first tray assembly 402, where the first tray assembly 402 is loaded into the third receptor 628, which is fully retracted into the gantry nozzle 610.
In a second example, two beam control assemblies 400 are used to control the charged particle beam 268 in the charged particle cancer therapy system 100. In this example, a patient specific ridge filter 512 is loaded into a first tray assembly 402, which is loaded into the second receptor 627 and a patient specific aperture 513 is loaded into a second tray assembly 404, which is loaded into the first receptor 626 and the two associated tray connector/communicators 430 using the first receptor 626 and second receptor 627 communicate to the main controller 110 the patient specific tray inserts 510. The tray receiver assembly 620 is subsequently retracted one slot so that the patient specific ridge filter 512 and the patient specific aperture reside outside of and at the nozzle end 612 of the gantry nozzle 610.
In a third example, three beam control tray assemblies 400 are used, such as a range shifter 511 in a first tray inserted into the first receiving slot 403, a compensator in a second tray inserted into the second receiving slot 405, and an aperture in a third tray inserted into the third receiving slot 407.
Generally, any patient specific tray insert 510 is inserted into a tray frame 410 to form a beam control tray assembly 400 inserted into any slot of the tray receiver assembly 620 and the tray assembly is not retracted or retracted any distance into the gantry nozzle 610.
Herein, any number optionally refers to at least that number or less than that number.
Still yet another embodiment includes any combination and/or permutation of any of the elements described herein.
The particular implementations shown and described are illustrative of the invention and its best mode and are not intended to otherwise limit the scope of the present invention in any way. Indeed, for the sake of brevity, conventional manufacturing, connection, preparation, and other functional aspects of the system may not be described in detail. Furthermore, the connecting lines shown in the various figures are intended to represent exemplary functional relationships and/or physical couplings between the various elements. Many alternative or additional functional relationships or physical connections may be present in a practical system.
In the foregoing description, the invention has been described with reference to specific exemplary embodiments; however, it will be appreciated that various modifications and changes may be made without departing from the scope of the present invention as set forth herein. The description and figures are to be regarded in an illustrative manner, rather than a restrictive one and all such modifications are intended to be included within the scope of the present invention. Accordingly, the scope of the invention should be determined by the generic embodiments described herein and their legal equivalents rather than by merely the specific examples described above. For example, the steps recited in any method or process embodiment may be executed in any order and are not limited to the explicit order presented in the specific examples. Additionally, the components and/or elements recited in any apparatus embodiment may be assembled or otherwise operationally configured in a variety of permutations to produce substantially the same result as the present invention and are accordingly not limited to the specific configuration recited in the specific examples.
Benefits, other advantages and solutions to problems have been described above with regard to particular embodiments; however, any benefit, advantage, solution to problems or any element that may cause any particular benefit, advantage or solution to occur or to become more pronounced are not to be construed as critical, required or essential features or components.
As used herein, the terms “comprises”, “comprising”, or any variation thereof, are intended to reference a non-exclusive inclusion, such that a process, method, article, composition or apparatus that comprises a list of elements does not include only those elements recited, but may also include other elements not expressly listed or inherent to such process, method, article, composition or apparatus. Other combinations and/or modifications of the above-described structures, arrangements, applications, proportions, elements, materials or components used in the practice of the present invention, in addition to those not specifically recited, may be varied or otherwise particularly adapted to specific environments, manufacturing specifications, design parameters or other operating requirements without departing from the general principles of the same.
Although the invention has been described herein with reference to certain preferred embodiments, one skilled in the art will readily appreciate that other applications may be substituted for those set forth herein without departing from the spirit and scope of the present invention. Accordingly, the invention should only be limited by the Claims included below.
This application is a continuation of U.S. patent application Ser. No. 15/073,471, filed Mar. 17, 2016 which claims the benefit of U.S. provisional patent application No. 62/304,839 filed Mar. 7, 2016 all of which are incorporated herein in their entirety by this reference thereto.
Number | Name | Date | Kind |
---|---|---|---|
2306875 | Fremlin | Dec 1942 | A |
2533688 | Quam | Dec 1950 | A |
2613726 | Paatero | Oct 1952 | A |
2790902 | Wright | Apr 1957 | A |
3128405 | Lambertson | Apr 1964 | A |
3412337 | Lothrop | Nov 1968 | A |
3582650 | Avery | Jun 1971 | A |
3585386 | Horton | Jun 1971 | A |
3655968 | Moore | Apr 1972 | A |
3867705 | Hudson | Feb 1975 | A |
3882339 | Rate | May 1975 | A |
3906280 | Andelfinger | Sep 1975 | A |
3911280 | Hyman et al. | Oct 1975 | A |
4002912 | Johnson | Jan 1977 | A |
4344011 | Hayashi | Aug 1982 | A |
4472822 | Swift | Sep 1984 | A |
4607380 | Oliver | Aug 1986 | A |
4622687 | Whitaker | Nov 1986 | A |
4705955 | Mileikowsky | Nov 1987 | A |
4726046 | Nunan | Feb 1988 | A |
4730353 | Ono | Mar 1988 | A |
4740758 | Ries | Apr 1988 | A |
4843333 | Marsing et al. | Jun 1989 | A |
4868844 | Nunan | Sep 1989 | A |
4870287 | Cole | Sep 1989 | A |
4908580 | Yamada et al. | Mar 1990 | A |
4989225 | Gupta et al. | Jan 1991 | A |
4992746 | Martin | Feb 1991 | A |
4996496 | Kitamura et al. | Feb 1991 | A |
4998258 | Ikeda | Mar 1991 | A |
5010562 | Hernandez et al. | Apr 1991 | A |
5017789 | Young | May 1991 | A |
5017882 | Finlan | May 1991 | A |
5039867 | Nishihara | Aug 1991 | A |
5046078 | Hernandez et al. | Sep 1991 | A |
5073913 | Martin | Dec 1991 | A |
5098158 | Palarski | Mar 1992 | A |
5101169 | Gomei | Mar 1992 | A |
5117194 | Nakanishi | May 1992 | A |
5168241 | Hirota | Dec 1992 | A |
5168514 | Horton | Dec 1992 | A |
5177448 | Ikeguchi | Jan 1993 | A |
5216377 | Nakata | Jun 1993 | A |
5260581 | Lesyna | Nov 1993 | A |
5285166 | Hiramoto | Feb 1994 | A |
5349198 | Takanaka | Sep 1994 | A |
5363008 | Hiramoto | Nov 1994 | A |
5388580 | Sullivan | Feb 1995 | A |
5402462 | Nobuta | Mar 1995 | A |
5423328 | Gavish | Jun 1995 | A |
5440133 | Moyers | Aug 1995 | A |
5483129 | Yamamoto | Jan 1996 | A |
5511549 | Legg | Apr 1996 | A |
5538494 | Matsuda | Jul 1996 | A |
5568109 | Takayama | Oct 1996 | A |
5576549 | Hell | Nov 1996 | A |
5576602 | Hiramoto | Nov 1996 | A |
5585642 | Britton | Dec 1996 | A |
5595191 | Kirk | Jan 1997 | A |
5600213 | Hiramoto | Feb 1997 | A |
5626682 | Kobari | May 1997 | A |
5633907 | Gravelle | May 1997 | A |
5642302 | Dumont | Jun 1997 | A |
5659223 | Goodman | Aug 1997 | A |
5661366 | Hirota | Aug 1997 | A |
5668371 | Deasy | Sep 1997 | A |
5698954 | Hirota | Dec 1997 | A |
5760395 | Johnstone | Jun 1998 | A |
5789875 | Hiramoto | Aug 1998 | A |
5790997 | Ruehl | Aug 1998 | A |
5818058 | Nakanishi | Oct 1998 | A |
5820320 | Kobari | Oct 1998 | A |
5825845 | Blair | Oct 1998 | A |
5825847 | Ruth | Oct 1998 | A |
5854531 | Young et al. | Dec 1998 | A |
5866912 | Slater | Feb 1999 | A |
5895926 | Britton | Apr 1999 | A |
5907595 | Sommerer | May 1999 | A |
5917293 | Saito | Jun 1999 | A |
5949080 | Ueda et al. | Sep 1999 | A |
5969367 | Hiramoto | Oct 1999 | A |
5986274 | Akiyama | Nov 1999 | A |
5993373 | Nonaka | Nov 1999 | A |
6008499 | Hiramoto | Dec 1999 | A |
6034377 | Pu | Mar 2000 | A |
6057655 | Jongen | May 2000 | A |
6087670 | Hiramoto | Jul 2000 | A |
6087672 | Matsuda | Jul 2000 | A |
6148058 | Dobbs | Nov 2000 | A |
6201851 | Piestrup et al. | Mar 2001 | B1 |
6207952 | Kan | Mar 2001 | B1 |
6218675 | Akiyama | Apr 2001 | B1 |
6236043 | Tadokoro | May 2001 | B1 |
6265837 | Akiyama | Jul 2001 | B1 |
6282263 | Arndt | Aug 2001 | B1 |
6298260 | Sontag | Oct 2001 | B1 |
6316776 | Hiramoto | Nov 2001 | B1 |
6322249 | Wofford | Nov 2001 | B1 |
6335535 | Miyake | Jan 2002 | B1 |
6339635 | Schardt | Jan 2002 | B1 |
6356617 | Besch | Mar 2002 | B1 |
6365894 | Tadokoro | Apr 2002 | B2 |
6421416 | Sliski | Jul 2002 | B1 |
6433336 | Jongen | Aug 2002 | B1 |
6433349 | Akiyama | Aug 2002 | B2 |
6433494 | Kulish | Aug 2002 | B1 |
6437513 | Stelzer | Aug 2002 | B1 |
6444990 | Morgan | Sep 2002 | B1 |
6462490 | Matsuda | Oct 2002 | B1 |
6470068 | Cheng | Oct 2002 | B2 |
6472834 | Hiramoto | Oct 2002 | B2 |
6476403 | Dolinskii | Nov 2002 | B1 |
6545436 | Gary | Apr 2003 | B1 |
6560354 | Maurer, Jr. | May 2003 | B1 |
6580084 | Hiramoto | Jun 2003 | B1 |
6597005 | Badura | Jul 2003 | B1 |
6600164 | Badura | Jul 2003 | B1 |
6614038 | Brand | Sep 2003 | B1 |
6617598 | Matsuda | Sep 2003 | B1 |
6626842 | Oka | Sep 2003 | B2 |
6635882 | Pavlovic | Oct 2003 | B1 |
6639234 | Badura | Oct 2003 | B1 |
6670618 | Hartmann | Dec 2003 | B1 |
6683318 | Haberer | Jan 2004 | B1 |
6683426 | Kleeven | Jan 2004 | B1 |
6710362 | Kraft | Mar 2004 | B2 |
6717162 | Jongen | Apr 2004 | B1 |
6725078 | Bucholz | Apr 2004 | B2 |
6730921 | Kraft | May 2004 | B2 |
6736831 | Hartmann | May 2004 | B1 |
6745072 | Badura | Jun 2004 | B1 |
6774383 | Norimine | Aug 2004 | B2 |
6777700 | Yanagisawa | Aug 2004 | B2 |
6785359 | Lemaitre | Aug 2004 | B2 |
6787771 | Bashkirov | Sep 2004 | B2 |
6792078 | Kato | Sep 2004 | B2 |
6799068 | Hartmann | Sep 2004 | B1 |
6800866 | Amemiya | Oct 2004 | B2 |
6803591 | Muramatsu | Oct 2004 | B2 |
6809325 | Dahl | Oct 2004 | B2 |
6819743 | Kato | Nov 2004 | B2 |
6822244 | Beloussov | Nov 2004 | B2 |
6823045 | Kato | Nov 2004 | B2 |
6838676 | Jackson | Jan 2005 | B1 |
6842502 | Jaffray | Jan 2005 | B2 |
6859741 | Haberer | Feb 2005 | B2 |
6862469 | Bucholz | Mar 2005 | B2 |
6873123 | Marchand | Mar 2005 | B2 |
6881970 | Akiyama | Apr 2005 | B2 |
6891177 | Kraft | May 2005 | B1 |
6897451 | Kaercher | May 2005 | B2 |
6900446 | Akiyama | May 2005 | B2 |
6903351 | Akiyama | Jun 2005 | B1 |
6903356 | Muramatsu | Jun 2005 | B2 |
6931100 | Kato | Aug 2005 | B2 |
6936832 | Norimine | Aug 2005 | B2 |
6937696 | Mostafavi | Aug 2005 | B1 |
6953943 | Yanagisawa | Oct 2005 | B2 |
6979832 | Yanagisawa | Dec 2005 | B2 |
6984835 | Harada | Jan 2006 | B2 |
6992312 | Yanagisawa | Jan 2006 | B2 |
6998258 | Kesseler | Feb 2006 | B1 |
7012267 | Moriyama | Mar 2006 | B2 |
7026636 | Yanagisawa | Apr 2006 | B2 |
7030396 | Muramatsu | Apr 2006 | B2 |
7045781 | Adamec | May 2006 | B2 |
7049613 | Yanagisawa | May 2006 | B2 |
7053389 | Yanagisawa | May 2006 | B2 |
7054801 | Sakamoto | May 2006 | B2 |
7058158 | Sako | Jun 2006 | B2 |
7060997 | Norimine | Jun 2006 | B2 |
7071479 | Yanagisawa | Jul 2006 | B2 |
7081619 | Bashkirov | Jul 2006 | B2 |
7084410 | Beloussov | Aug 2006 | B2 |
7091478 | Haberer | Aug 2006 | B2 |
7102144 | Matsuda | Sep 2006 | B2 |
7109505 | Sliski | Sep 2006 | B1 |
7122811 | Matsuda | Oct 2006 | B2 |
7141810 | Kakiuchi | Nov 2006 | B2 |
7154107 | Yanagisawa | Dec 2006 | B2 |
7154108 | Tadokoro | Dec 2006 | B2 |
7173264 | Moriyama | Feb 2007 | B2 |
7173265 | Miller | Feb 2007 | B2 |
7193227 | Hiramoto | Mar 2007 | B2 |
7199382 | Rigney | Apr 2007 | B2 |
7208748 | Sliski | Apr 2007 | B2 |
7212608 | Nagamine | May 2007 | B2 |
7212609 | Nagamine | May 2007 | B2 |
7227161 | Matsuda | Jun 2007 | B2 |
7247869 | Tadokoro | Jul 2007 | B2 |
7252745 | Gorokhovsky | Aug 2007 | B2 |
7259529 | Tanaka | Aug 2007 | B2 |
7262424 | Moriyama | Aug 2007 | B2 |
7274018 | Adamec | Sep 2007 | B2 |
7274025 | Berdermann | Sep 2007 | B2 |
7280633 | Cheng | Oct 2007 | B2 |
7297967 | Yanagisawa | Nov 2007 | B2 |
7301162 | Matsuda | Nov 2007 | B2 |
7307264 | Brusasco | Dec 2007 | B2 |
7310404 | Tashiro | Dec 2007 | B2 |
7315606 | Tsujii | Jan 2008 | B2 |
7319231 | Moriyama | Jan 2008 | B2 |
7342516 | Kato et al. | Mar 2008 | B2 |
7345291 | Kats | Mar 2008 | B2 |
7345292 | Moriyama | Mar 2008 | B2 |
7349522 | Yan et al. | Mar 2008 | B2 |
7351988 | Naumann | Apr 2008 | B2 |
7355189 | Yanagisawa | Apr 2008 | B2 |
7356112 | Brown | Apr 2008 | B2 |
7368740 | Beloussov | May 2008 | B2 |
7372053 | Yamashita | May 2008 | B2 |
7378672 | Harada | May 2008 | B2 |
7381979 | Yamashita | Jun 2008 | B2 |
7385203 | Nakayama | Jun 2008 | B2 |
7394082 | Fujimaki | Jul 2008 | B2 |
7397054 | Natori | Jul 2008 | B2 |
7397901 | Johnsen | Jul 2008 | B1 |
7402822 | Guertin | Jul 2008 | B2 |
7402823 | Guertin | Jul 2008 | B2 |
7402824 | Guertin | Jul 2008 | B2 |
7402963 | Sliski | Jul 2008 | B2 |
7425717 | Matsuda | Sep 2008 | B2 |
7432516 | Peggs | Oct 2008 | B2 |
7439528 | Nishiuchi | Oct 2008 | B2 |
7446490 | Jongen | Nov 2008 | B2 |
7449701 | Fujimaki | Nov 2008 | B2 |
7453076 | Welch et al. | Nov 2008 | B2 |
7456415 | Yanagisawa | Nov 2008 | B2 |
7456591 | Jongen | Nov 2008 | B2 |
7465944 | Ueno | Dec 2008 | B2 |
7471765 | Jaffray | Dec 2008 | B2 |
7476883 | Nutt | Jan 2009 | B2 |
7492858 | Partain | Feb 2009 | B2 |
7531818 | Brahme | May 2009 | B2 |
7555103 | Johnsen | Jun 2009 | B2 |
7560717 | Matsuda | Jul 2009 | B2 |
7576342 | Hiramoto | Aug 2009 | B2 |
7586112 | Chiba | Sep 2009 | B2 |
7589334 | Hiramoto | Sep 2009 | B2 |
7626347 | Sliski | Dec 2009 | B2 |
7634057 | Ein-Gal | Dec 2009 | B2 |
7659521 | Pedroni | Feb 2010 | B2 |
7668585 | Green | Feb 2010 | B2 |
7692168 | Moriyama | Apr 2010 | B2 |
7701677 | Schultz | Apr 2010 | B2 |
7709818 | Matsuda | May 2010 | B2 |
7718982 | Sliski | May 2010 | B2 |
7728311 | Gall | Jun 2010 | B2 |
7729469 | Kobayashi | Jun 2010 | B2 |
7741623 | Sommer | Jun 2010 | B2 |
7755305 | Umezawa | Jul 2010 | B2 |
7772577 | Saito | Aug 2010 | B2 |
7796730 | Marash | Sep 2010 | B2 |
7801277 | Zou | Sep 2010 | B2 |
7807982 | Nishiuchi | Oct 2010 | B2 |
7817774 | Partain | Oct 2010 | B2 |
7817778 | Nord | Oct 2010 | B2 |
7825388 | Nihongi | Nov 2010 | B2 |
7826592 | Jaffray | Nov 2010 | B2 |
7826593 | Svensson | Nov 2010 | B2 |
7834336 | Boeh | Nov 2010 | B2 |
7838855 | Fujii | Nov 2010 | B2 |
7848488 | Mansfield | Dec 2010 | B2 |
7860216 | Jongen | Dec 2010 | B2 |
7875868 | Moriyama | Jan 2011 | B2 |
7894574 | Nord | Feb 2011 | B1 |
7906769 | Blasche | Mar 2011 | B2 |
7919765 | Timmer | Apr 2011 | B2 |
7939809 | Balakin | May 2011 | B2 |
7940891 | Star-Lack | May 2011 | B2 |
7940894 | Balakin | May 2011 | B2 |
7943913 | Balakin | May 2011 | B2 |
7953205 | Balakin | May 2011 | B2 |
7961844 | Takeda | Jun 2011 | B2 |
7977656 | Fujimaki | Jul 2011 | B2 |
7982198 | Nishiuchi | Jul 2011 | B2 |
7987053 | Schaffner | Jul 2011 | B2 |
7995813 | Foshee | Aug 2011 | B2 |
8002465 | Ahn | Aug 2011 | B2 |
8003964 | Stark | Aug 2011 | B2 |
8009804 | Siljamaki | Aug 2011 | B2 |
8045679 | Balakin | Oct 2011 | B2 |
8067748 | Balakin | Nov 2011 | B2 |
8089054 | Balakin | Jan 2012 | B2 |
8093564 | Balakin | Jan 2012 | B2 |
8139712 | Kojima | Mar 2012 | B2 |
8309941 | Balakin | Nov 2012 | B2 |
8374314 | Balakin | Feb 2013 | B2 |
20010009267 | Tadokoro | Jul 2001 | A1 |
20030031297 | Mateo | Feb 2003 | A1 |
20030141460 | Kraft | Jul 2003 | A1 |
20030163015 | Yanagisawa | Aug 2003 | A1 |
20030164459 | Schardt | Sep 2003 | A1 |
20040022361 | Lemaitre | Feb 2004 | A1 |
20040062354 | Kato | Apr 2004 | A1 |
20040155206 | Marchand | Aug 2004 | A1 |
20040184583 | Nagamine et al. | Sep 2004 | A1 |
20040218725 | Radley | Nov 2004 | A1 |
20040227074 | Benveniste et al. | Nov 2004 | A1 |
20040254492 | Zhang | Dec 2004 | A1 |
20050017193 | Jackson | Jan 2005 | A1 |
20050051740 | Yanagisawa | Mar 2005 | A1 |
20050099145 | Nishiuchi et al. | May 2005 | A1 |
20050148808 | Cameron | Jul 2005 | A1 |
20050161618 | Pedroni | Jul 2005 | A1 |
20050167610 | Tajima | Aug 2005 | A1 |
20050211905 | Stark | Sep 2005 | A1 |
20050238134 | Brusasco | Oct 2005 | A1 |
20050269497 | Jongen | Dec 2005 | A1 |
20050284233 | Teraura et al. | Dec 2005 | A1 |
20060015202 | Sweat | Jan 2006 | A1 |
20060050848 | Vilsmeier | Mar 2006 | A1 |
20060106301 | Kats | May 2006 | A1 |
20060163495 | Hiramoto | Jul 2006 | A1 |
20060171508 | Noda | Aug 2006 | A1 |
20060180158 | McKnight et al. | Aug 2006 | A1 |
20060226372 | Yanagisawa | Oct 2006 | A1 |
20060255285 | Jongen | Nov 2006 | A1 |
20060262898 | Partain | Nov 2006 | A1 |
20070018121 | Leyman | Jan 2007 | A1 |
20070027389 | Wesse | Feb 2007 | A1 |
20070040115 | Publicover | Feb 2007 | A1 |
20070051905 | Fujimaki et al. | Mar 2007 | A1 |
20070093723 | Keall | Apr 2007 | A1 |
20070121788 | Mildner | May 2007 | A1 |
20070170994 | Peggs | Jul 2007 | A1 |
20070181815 | Ebstein | Aug 2007 | A1 |
20070189461 | Sommer | Aug 2007 | A1 |
20070211854 | Koshnitsky et al. | Sep 2007 | A1 |
20070215819 | Hiramoto | Sep 2007 | A1 |
20070228291 | Hiramoto | Oct 2007 | A1 |
20070228304 | Nishiuchi | Oct 2007 | A1 |
20070269000 | Partain et al. | Nov 2007 | A1 |
20080023644 | Pedroni | Jan 2008 | A1 |
20080067405 | Nihongi et al. | Mar 2008 | A1 |
20080093567 | Gall | Apr 2008 | A1 |
20080139955 | Hansmann | Jun 2008 | A1 |
20080191142 | Pedroni | Aug 2008 | A1 |
20080267352 | Aoi | Oct 2008 | A1 |
20080290297 | Blasche et al. | Nov 2008 | A1 |
20080317202 | Partain et al. | Dec 2008 | A1 |
20090096179 | Stark | Apr 2009 | A1 |
20090140672 | Gall | Jun 2009 | A1 |
20090168960 | Jongen | Jul 2009 | A1 |
20090184263 | Moriyama | Jul 2009 | A1 |
20090189095 | Flynn | Jul 2009 | A1 |
20090200483 | Gall | Aug 2009 | A1 |
20090236545 | Timmer | Sep 2009 | A1 |
20090261248 | Glavish et al. | Oct 2009 | A1 |
20090283704 | Nishiuchi | Nov 2009 | A1 |
20090289194 | Saito | Nov 2009 | A1 |
20090304153 | Amelia | Dec 2009 | A1 |
20090314960 | Balakin | Dec 2009 | A1 |
20090314961 | Balakin | Dec 2009 | A1 |
20100001212 | Nishiuchi | Jan 2010 | A1 |
20100006106 | Balakin | Jan 2010 | A1 |
20100008468 | Balakin | Jan 2010 | A1 |
20100008469 | Balakin | Jan 2010 | A1 |
20100027745 | Balakin | Feb 2010 | A1 |
20100033115 | Cleland | Feb 2010 | A1 |
20100045213 | Sliski | Feb 2010 | A1 |
20100059688 | Claereboudt | Mar 2010 | A1 |
20100060209 | Balakin | Mar 2010 | A1 |
20100090122 | Balakin | Apr 2010 | A1 |
20100091948 | Balakin | Apr 2010 | A1 |
20100128846 | Balakin | May 2010 | A1 |
20100230617 | Gall | Sep 2010 | A1 |
20100272241 | Amelia | Oct 2010 | A1 |
20100308235 | Sliski | Dec 2010 | A1 |
20110073778 | Natori | Mar 2011 | A1 |
20110080172 | Banning-Geertsma | Apr 2011 | A1 |
20110089329 | Jongen | Apr 2011 | A1 |
20110127443 | Comer | Jun 2011 | A1 |
20110137159 | Jongen | Jun 2011 | A1 |
20110147608 | Balakin | Jun 2011 | A1 |
20110174984 | Balakin | Jul 2011 | A1 |
20110178359 | Hirschman et al. | Jul 2011 | A1 |
20110186720 | Jongen | Aug 2011 | A1 |
20110233423 | Balakin | Sep 2011 | A1 |
20110278477 | Balakin | Nov 2011 | A1 |
20110284760 | Balakin | Nov 2011 | A1 |
20110284762 | Balakin | Nov 2011 | A1 |
20110313232 | Balakin | Dec 2011 | A1 |
20120043472 | Balakin | Feb 2012 | A1 |
20120205551 | Balakin | Aug 2012 | A1 |
20120209109 | Balakin | Aug 2012 | A1 |
20160045769 | Amelia | Feb 2016 | A1 |
Number | Date | Country |
---|---|---|
1683545 | Jul 2006 | EP |
1270619 | Apr 1972 | GB |
WO 9953998 | Oct 1999 | WO |
WO 014026 | Jan 2007 | WO |
WO 2008044194 | Apr 2008 | WO |
WO2010101489 | Mar 2009 | WO |
WO 2009142546 | Nov 2009 | WO |
WO 2009142550 | Nov 2009 | WO |
Entry |
---|
Adams, “Electrostatic cylinder lenses II: Three Element Einzel Lenses”, Journal, Feb. 1, 1972, pp. 150-155, XP002554355, vol. 5 No. 2, Journal of Physics E. |
Amaldi, “A Hospital-Based Hadrontherapy Complex”, Journal, Jun. 27, 1994, pp. 49-51, XP002552288, Proceedings of Epac 94, London, England. |
Arimoto, “A Study of the PRISM-FFAG Magnet”, Journal, Oct. 18, 2004,Oct. 22, 2004, pp. 243-245, XP002551810, Proceedings of Cyclotron 2004 Conference, Tokyo, Japan. |
Biophysics Group et al. “Design, Construction and First Experiment of a Magnetic Scanning System for Therapy, Radiobiological Experiment on the Radiobiological Action of Carbon, Oxygen and Neon” GSI Report, Gessellschaft fur Schwerionenforschung MBH. vol. GSI-91-18, Jun. 1, 1991, pp. 1-31. |
Blackmore, “Operation of the TRIUMF Proton Therapy Facility”, Book, May 12, 1997, pp. 3831-3833, XP010322373, vol. 3, Proceedings of the 1997 Particle Accelerator Conference, NJ, USA. |
Bryant, “Proton-Ion Medical Machine Study (PIMMS) Part II”, Book, Jul. 27, 2000, p. 23,p. 228,pp. 289-290, XP002551811, European Organisation for Nuclear Research Cern-Ps Division, Geneva, Switzerland. |
Craddock, “New Concepts in FFAG Design for Secondary Beam Facilities and other Applications”, Journal, May 16, 2005,May 20, 2005, pp. 261-265, XP002551806, Proceedings of 2005 Particle Accelerator Conference, Knoxville, Tennessee, USA. |
Dzhelepov, “Use of USSR Proton Accelerators for Medical Purposes”, Journal,Jun. 1973, pp. 268-270, vol. ns-2—No. 3, XP002553045, IEEE Transactions on Nuclear Science USA, USA. |
Endo, “Medical Synchrotron for Proton Therapy” Journal, Jun. 7, 1988,Jun. 11, 1988, pp. 1459-1461, XP002551808, Proceedings of Epac 88, Rome, Italy. |
European Organization for Nuclear Research Cern, Jul. 27, 2000, pp. 1-352. |
Johnstone, Koscielniak, “Tune-Stabilized Linear-Field FFAG for Carbon Therapy”, Journal, Jun. 26, 2006,Jun. 30, 2006, XP002551807, Proceedings of EPAC 2006, Edinburgh, Scotland, UK. |
Kalnins, “The use of electric multiple lenses for bending and focusing polar molecules, with application to the design of a rotational-state separator”, Journal, May 17, 2003,May 21, 2003, pp. 2951-2953, XP002554356, Proceeding of Pac 2003, Portland, Oregon, USA. |
Kim, “50 MeV Proton Beam Test Facility for Low Flux Beam Utilization Studies of PEFP”, Journal, Oct. 31, 2005, pp. 441-443, XP002568008, Proceedings of Apac 2004, Pohang, Korea. |
Lapostolle, “Introduction a la theorie des accelerateurs lineaires”, Book, Jul. 10, 1987, pp. 4-5, XP002554354, Cern Yellow Book Cern, Geneva, Switzerland. |
Li, “A thin Beryllium Injection Window for CESR-C”, Book, May 12, 2003, pp. 2264-2266, XP002568010, vol. 4, PAC03, Portland, Oregon, USA. |
Noda, “Slow beam extraction by a transverse RF field with AM and FM”, Journal, May 21, 1996, pp. 269-277, vol. A374, XP002552289, Nuclear Instruments and Methods in Physics Research A, Eslevier, Amsterdam, NL. |
Noda, “Performance of a respiration-gated beam control system for patient treatment”, Journal, Jun. 10, 1996, Jun. 14, 1996, pp. 2656-2658, XP002552290, Proceedings Epac 96, Barcelona, Spain. |
Peters, “Negative ion sources for high energy accelerators”, Journal, Feb. 1, 2000, pp. 1069-1074, XP012037926, vol. 71—No. 2,Review of Scientific Instruments, Melville, NY, USA. |
Pohlit, “Optimization of Cancer Treatment with Accelerator Produced Radiations”, Journal, Jun. 22, 1998, pp. 192-194, XP002552855, Proceedings EPAC 98, Stockholm, Sweden. |
Proceeding of 2004 Cyclotron Conference, Oct. 18, 2004, pp. 246-428. |
Proceedings of Cyclotron 2004 Conference, Oct. 18, 2004, pp. 243-245 (Presentation Material pp. 1-30). |
Proceedings of EPAC 2006, Jun. 30, 2006, pp. 2290-2292. |
Proceeding of 2005 Particle Accelerator Conference, May 16, 2005, pp. 261-265. |
Saito, “RF Accelerating System for Compact Ion Synchrotron”, Journal, Jun. 18, 2001, pp. 966-968, XP002568009, Proceeding of 2001 Pac, Chicago, USA. |
Suda, “Medical Application of the Positron Emitter Beam at HIMAC”, Journal, Jun. 26, 2000, Jun. 30, 2000 pp. 2554-2556, XP002553046, Proceedings of EPAC 2000, Vienna, Austria. |
Tanigaki, “Construction of FFAG Accelerators in KURRI for ADS Study”, May 16, 2005,May 20, 2005, pp. 350-352, XP002551809, Proceedings of 2005 Particle Accelerator Conference, Knoxville, Tennessee, USA. |
Trbojevic, “Design of a Non-Scaling FFAG Accelerator for Proton Therapy”, Journal, Oct. 18, 2004,Oct. 22, 2004, pp. 246-248, XP002551805, Proceedings of 2004 Cyclotron Conference, Tokyo, Japan. |
Winkler, “Charge Exchange Extraction at the Experimental Storage Ring ESR at GSI”, Journal, Jun. 22, 1998, p. 559-561, XP002552287, Proceedings of Epac 98, Stockholm, Sweden. |
Number | Date | Country | |
---|---|---|---|
20170252580 A1 | Sep 2017 | US |
Number | Date | Country | |
---|---|---|---|
62304839 | Mar 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15073471 | Mar 2016 | US |
Child | 15382401 | US |